SYDNEY JOHNSTON: Open Payments
NPI 1619502341 · LINCOLN, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,330 in 47 payments from 13 companies in 2025. Trend: 2023 $433 · 2024 $1,014 · 2025 $1,330
Food & beverage: $1,258Education: $72
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 30 | $824 |
| AstraZeneca Pharmaceuticals LP | 3 | $203 |
| SANOFI-AVENTIS U.S. LLC | 1 | $72 |
| Lilly USA, LLC | 3 | $56 |
| Amgen Inc. | 2 | $34 |
| Regeneron Healthcare Solutions, Inc. | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| PFIZER INC. | 1 | $19 |
| Novartis Pharmaceuticals Corporation | 1 | $19 |
| Arcutis Biotherapeutics, Inc. | 1 | $16 |
Products named: DUPIXENT, FASENRA, AYVAKIT, EBGLYSS, TEZSPIRE, EOHILIA, CIBINQO, Rhapsido.
Industry payments across NE — which companies pay providers there.
